Glycated Hemoglobin vs Fasting Plasma Glucose as a Predictor of Left Ventricular Dysfunction After ST-Elevation Myocardial Infarction

Tsai, Josh; Tian, Jenny; Wang, William Y.S.; Ng, Arnold C.T.

doi:10.1016/j.cjca.2014.10.029

Cited by 6 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 The high rates seen in the current study and in the AASK study (which was restricted to patients with both CKD and hypertension) are not surprising, as hypertension, CKD, and diabetes share common risk factors. The relatively low level of concordance among the measures of baseline glycemic control, consistent with other studies in high-risk 22 and patient (post-MI) 23 populations, raises questions about the best measure to use to characterize glycemic control status in persons with CKD. In the setting of CKD, numerous confounders may affect the legitimacy of the HbA1c assay 24 and HOMA-IR.…”

Section: Discussionsupporting

confidence: 54%

Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

Jepson

Hsu

Fischer

et al. 2019

American Journal of Kidney Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 54%

Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

Jepson

Hsu

Fischer

et al. 2019

American Journal of Kidney Diseases

View full text Add to dashboard Cite

show abstract

“…Previously, studies have indicated that this reduction in restenosis might have been obtained at the expense of a higher incidence of stent thrombosis that links stent implantation and adverse cardiac events such as recurrent myocardial infarction or death [76, 77]. Hence, we think multifactorial occurrence, including triple vessel disease, hyperlipidemia, higher BMI, HbA1C, and inflammation response that promote the association of stent implantation with the MACE in our study [66, 67, 69, 70, 75, 78]. In addition, there was no statistically significant difference in rate of MACE among 4 operators in the present study.…”

Section: Discussionmentioning

confidence: 76%

The burden of major adverse cardiac events in patients with coronary artery disease

Tsai

Wang

et al. 2017

BMC Cardiovasc Disord

119

View full text Add to dashboard Cite

BackgroundPatients with a history of cardiovascular disease are at high risk of developing secondary major adverse cardiac events (MACE). This study aimed to identify independent predictors of MACE after hospital admission which could be used to identify of high-risk patients who may benefit from preventive strategies.MethodsThis study included 1,520 consecutive patients with coronary artery disease (CAD) (654 with acute coronary syndrome (ACS) and 866 with elective percutaneous coronary intervention (PCI) patients) who received PCI and/or stenting. MACE was defined as all-cause mortality or rehospitalization for a cardiovascular- related illness. Cardiovascular-related illnesses included heart failure, reinfarction (nonfatal), recurrence of angina pectoris and repeat PCI or coronary artery bypass graft.ResultsDuring a mean follow-up period of 32 months, 558 of the 1,520 patients developed at least one MACE. Cox regression analysis showed that the baseline clinical and biochemical variables which associated with MACE were age, being illiterate, a widow or widower, and/or economically dependent, having triple vessel disease, stent implantation, anemia, and/or diabetes mellitus, waist to hip ratio (WHR), diastolic blood pressure, fasting glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), creatinine, estimated glomerular filtration rate (eGFR), red blood cell count, hemoglobin, hematocrit, and mean corpuscular-hemoglobin concentration (MCHC) in ACS patients, and age, malnourished, and/or economically dependent, taking hypoglycemic medication, having triple vessel disease, stent implantation, anemia, diabetes mellitus, and/or hypertension, WHR, fasting glucose, HDL-C, uric acid, creatinine, eGFR, high-sensitivity C-reactive protein, mean corpuscular volume, and MCHC in elective PCI patients. Using multivariate Cox regression analysis, we found the MACE’s independent factors are triple vessel disease, stent implantation, hypertension, and eGFR in ACS patients, and having triple vessel disease, stent implantation, hypertension, and uric acid in elective PCI patients.ConclusionsHaving triple vessel disease, stent implantation, hypertension, and eGFR or uric acid independently predicted MACE in patients with CAD after long-term follow-up. Fortunately, these factors are modifiable and should be identified and monitored early.

show abstract

“…Previous studies pointed out that poor glucose control might contribute to the formation of reactive oxygen species, which would result in myocarditis, myocardial necrosis, impaired endothelial function and compromised recovery from myocardial ischemia injury [36,37]. Evidence indicated that HbA 1c level was positively associated with left ventricular dysfunction and coronary artery severity among STEMI patients [38,39]. A randomized controlled trial based on 10,251 type 2 diabetes patients even showed that, participants in the intensive therapy group (HbA 1c < 6.0%) were less likely to experience MI than those in the standard therapy group (HbA 1c < 7.0%-7.9%) [40].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of glycated hemoglobin among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis

Hou

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:Many studies have shown the prognostic significance of glycated hemoglobin (HbA 1c ) for overall coronary artery disease (CAD). But less is known about the role that HbA 1c played in the prognosis of patients diagnosed with ST-segment elevation myocardial infarction (STEMI).Results from previous studies were controversial. Therefore, a meta-analysis was conducted to investigate whether admission HbA 1c level was a predictor of short-and longterm mortality rates among patients diagnosed with STEMI. Relevant literatures were retrieved from the electronic databases up to March 2016. Reference lists were hand searched to identify eligible studies. Articles were included if they provided sufficient information for the calculation of pooled relative risk (RR) and its corresponding 95% confidence interval (CI). Finally, we got 19 prospective studies involving a total of 35,994 STEMI patients to evaluate the associations between HbA 1c level and their in-hospital, 30-day and long-term mortality. Among STEMI patients, HbA 1c level was not significantly associated with in-hospital mortality (RR 1.20, 95% CI 0.95-1.53, p = 0.13). However, elevated HbA 1c level was positively associated with risk of 30-day and long-term mortality (for 30-day mortality, RR 1.25, 95% CI 1.03-1.52, p = 0.02; for long-term mortality, RR 1.45, 95% CI 1.20-1.76, p < 0.01). In conclusion, our findings suggested elevated HbA 1c level among STEMI patients was an indicator of 1.25-fold 30-day mortality risk and 1.45-fold long-term mortality risk, respectively. STEMI patients with high HbA 1c level should have their chronic glucose dysregulation under intensive control.

show abstract

Glycated Hemoglobin vs Fasting Plasma Glucose as a Predictor of Left Ventricular Dysfunction After ST-Elevation Myocardial Infarction

Cited by 6 publications

References 19 publications

Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

The burden of major adverse cardiac events in patients with coronary artery disease

Prognostic value of glycated hemoglobin among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis

Contact Info

Product

Resources

About